Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06937957 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of BR111 in Patients With Advanced Malignancies

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Aug 2028 to Oct 9, 2027
    • Study completion date: Dec 2028 to Dec 31, 2027
    • Start date changed from estimate of Apr 2025 to Apr 24, 2025
    • Site details revised
  2. Study title shortened, about 12 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR111-101 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR111-101 for injection in patients with advanced malignancies.
Trial Details
NCT Number NCT06937957
Lead Sponsor BioRay Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Advanced Malignancies
Enrollment 166 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov